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Introduction

Results

Conclusions

• Cardiogenic shock continues to be a prominent
cause of mortality in patients suffering from
1
various Cardiovascular issues.
• The Impella is a short-term ventricular assist
device that is inserted percutaneously into a
patients’ artery.
• The Impella device has shown to be a possible
treatment option for cardiogenic shock,
decreasing the mortality rate associated with
this condition. 2

• The approximate survival rate for patients after
receiving the Impella device implant is 61.3%.
(Figure 1)
• 51% of the patients had persisting cardiogenic
shock that led to or was a factor of their death.
• 14.5% of the patients experienced a
complication after the Impella device
implantation with Device Displacement being
the most common complication. (Figure 2)

Objectives

Future Directions

• Determine the effectiveness of Impella in the
treatment of cardiogenic shock.
• Analyze the outcome of patient survival rate
after Impella device insertion.

Figure 1. Kaplan Meier Curve for the survival rate for the Impella device 30 days after
insertion

Methods

• Extensive chart review of 55 adult patients
diagnosed with cardiogenic shock between
2018 and 2021 in a surgical cohort.
• Obtain patient demographics, date of Impella
insertion, Impella device size and/or type, and
outcome of support using patient charts in
EPIC.

• Continue to analyze the efficiency of the
Impella device in a clinical setting and use
results to modify treatment plans if necessary.
• Examine the outcome of Impella support in
pediatric cardiovascular care, along with adult
treatment of cardiogenic shock.
• Investigate differences in Impella device sizes
in the treatment of cardiogenic shock.
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Figure 2. Summary of medical complications resulting from Impella device implant
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